Biogen (NASDAQ:BIIB) Announces Quarterly Earnings Results, Beats Estimates By $0.22 EPS

Biogen (NASDAQ:BIIB) announced its earnings results on Wednesday. The biotechnology company reported $3.67 earnings per share for the quarter, beating the consensus estimate of $3.45 by $0.22, Briefing.com reports. Biogen had a return on equity of 14.91% and a net margin of 11.81%. The business had revenue of $2.29 billion during the quarter, compared to analysts’ expectations of $2.31 billion. During the same quarter last year, the business posted $3.40 earnings per share. The company’s quarterly revenue was down 7.0% on a year-over-year basis. Biogen updated its FY24 guidance to $15.00-16.00 EPS and its FY 2024 guidance to 15.000-16.000 EPS.

Biogen Stock Down 1.2 %

Shares of BIIB traded down $2.52 during midday trading on Thursday, reaching $199.47. 414,849 shares of the stock were exchanged, compared to its average volume of 1,181,590. Biogen has a 12-month low of $189.44 and a 12-month high of $319.76. The firm has a 50 day simple moving average of $213.18 and a 200-day simple moving average of $234.39. The company has a quick ratio of 1.26, a current ratio of 2.00 and a debt-to-equity ratio of 0.46. The company has a market cap of $28.99 billion, a price-to-earnings ratio of 25.31, a P/E/G ratio of 1.84 and a beta of -0.02.

Insider Transactions at Biogen

In related news, insider Priya Singhal sold 419 shares of the firm’s stock in a transaction that occurred on Monday, February 12th. The stock was sold at an average price of $239.45, for a total value of $100,329.55. Following the transaction, the insider now directly owns 4,516 shares of the company’s stock, valued at approximately $1,081,356.20. The sale was disclosed in a document filed with the Securities & Exchange Commission, which can be accessed through this hyperlink. In related news, Director Eric K. Rowinsky acquired 455 shares of the business’s stock in a transaction that occurred on Thursday, February 15th. The shares were acquired at an average cost of $222.54 per share, with a total value of $101,255.70. Following the purchase, the director now owns 20,629 shares of the company’s stock, valued at $4,590,777.66. The acquisition was disclosed in a legal filing with the Securities & Exchange Commission, which can be accessed through this hyperlink. Also, insider Priya Singhal sold 419 shares of the firm’s stock in a transaction that occurred on Monday, February 12th. The shares were sold at an average price of $239.45, for a total value of $100,329.55. Following the completion of the transaction, the insider now directly owns 4,516 shares in the company, valued at $1,081,356.20. The disclosure for this sale can be found here. Insiders sold 882 shares of company stock valued at $202,030 in the last three months. Corporate insiders own 0.60% of the company’s stock.

Analyst Ratings Changes

BIIB has been the subject of a number of recent analyst reports. William Blair reiterated an “outperform” rating on shares of Biogen in a research report on Monday, April 1st. Bank Of America (Bofa) decreased their price target on Biogen from $290.00 to $280.00 and set a “neutral” rating for the company in a research report on Monday, February 12th. BMO Capital Markets decreased their price target on Biogen from $295.00 to $285.00 and set an “outperform” rating for the company in a research report on Wednesday, February 14th. BTIG Research reiterated a “neutral” rating on shares of Biogen in a research report on Sunday, January 7th. Finally, Wedbush increased their price target on Biogen from $213.00 to $215.00 and gave the company a “neutral” rating in a research report on Thursday. Ten investment analysts have rated the stock with a hold rating and eighteen have issued a buy rating to the company’s stock. According to data from MarketBeat.com, the stock currently has an average rating of “Moderate Buy” and a consensus target price of $294.46.

Biogen Company Profile

Biogen Inc discovers, develops, manufactures, and delivers therapies for treating neurological and neurodegenerative diseases in the United States, Europe, Germany, Asia, and internationally. The company provides TECFIDERA, VUMERITY, AVONEX, PLEGRIDY, TYSABRI, and FAMPYRA for multiple sclerosis (MS); SPINRAZA for spinal muscular atrophy; ADUHELM to treat Alzheimer's disease; FUMADERM to treat plaque psoriasis; BENEPALI, an etanercept biosimilar referencing ENBREL; IMRALDI, an adalimumab biosimilar referencing HUMIRA; FLIXABI, an infliximab biosimilar referencing REMICADE; and BYOOVIZ, a ranibizumab biosimilar referencing LUCENTIS.